Suneel Gupta

Suneel is currently the Chief Scientific Officer at Impax Pharmaceuticals, having joined them in 2008. Previously, he was with ALZA Corporation, a wholly-owned subsidiary of Johnson & Johnson, for nearly 20 years. There, he was responsible for the strategic vision and execution of clinical research and development as Senior Vice President and distinguished research fellow. Suneel’s research interest focuses on the influence of rate and route of drug delivery to discover new indications, as well as maximize clinical utility and/or effectiveness. With extensive experience in the development of drug delivery based products across many therapeutic areas, Suneel has made significant contributions to the development of several therapeutics including Duragesic®, Durotap®, Nicoderm®, Testoderm®, Effidac®, Covera-HS®, Ditropan-XL®, Concerta®, Ionsys®, Jurnista®, Invega®, and Priligy®. Before ALZA, he worked at Ciba Geigy (India) where he was responsible for the scale-up and manufacturing of several products. Suneel received his Ph.D. from the University of Manchester and was a Postdoctoral Fellow at UCSF. He is a co-author on more than 200 research publications and co-inventor on more than 40 patents.